Living with Rheumatic Mitral Stenosis and a Dilated Left Atrium

Rheumatic mitral stenosis is a serious heart condition that affects millions worldwide. It occurs when the mitral valve, which regulates blood flow between the left atrium and left ventricle, becomes narrowed due to rheumatic fever. This narrowing obstructs blood flow, causing the left atrium to dilate or enlarge. Above Video is showing Rheumatic Mitral Valve Stenosis with dilated LA.

Symptoms

People with rheumatic mitral stenosis and a dilated left atrium may experience:

- Shortness of breath (dyspnea) during physical activity or at rest
- Fatigue and weakness
- Swelling in the legs, ankles, and feet (edema)
- Palpitations or irregular heartbeats
- Coughing up blood or pink, frothy mucus

Diagnosis

Diagnosing rheumatic mitral stenosis involves:

- Physical examination and medical history
- Echocardiogram (ultrasound of the heart) to visualize the mitral valve and left atrium
- Electrocardiogram (ECG) to assess heart rhythm
- Chest X-ray to evaluate lung congestion

Treatment

Treatment focuses on managing symptoms, preventing complications, and repairing or replacing the damaged mitral valve:

- Medications to control symptoms, such as diuretics, beta blockers, and anticoagulants
- Balloon mitral valvuloplasty (BMV) to widen the narrowed valve
- Surgical mitral valve repair or replacement
- Anticoagulation therapy to prevent stroke

Lifestyle Changes

Making healthy lifestyle choices can help manage rheumatic mitral stenosis:

- Regular exercise, such as walking or swimming, to improve cardiovascular health
- A balanced diet low in salt, sugar, and unhealthy fats
- Stress reduction techniques, such as meditation or yoga
- Quitting smoking and limiting alcohol consumption
- Regular follow-up appointments with your healthcare provider

Prognosis

With proper treatment and lifestyle changes, people with rheumatic mitral stenosis can lead active and fulfilling lives. However, if left untreated, the condition can lead to serious complications, such as:

- Heart failure
- Stroke
- Pulmonary hypertension
- Atrial fibrillation

Early diagnosis and treatment are crucial to managing rheumatic mitral stenosis and preventing long-term damage.

Comments

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

𝘼𝙣𝙩𝙞𝙘𝙤𝙖𝙜𝙪𝙡𝙖𝙩𝙞𝙤𝙣 𝘼𝙛𝙩𝙚𝙧 𝙎𝙩𝙧𝙤𝙠𝙚

𝘼𝙣𝙩𝙞𝙘𝙤𝙖𝙜𝙪𝙡𝙖𝙩𝙞𝙤𝙣 𝘼𝙛𝙩𝙚𝙧 𝙎𝙩𝙧𝙤𝙠𝙚 in Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts. The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.

2025 ESC Guidelines on INR Targets in Mechanical Valves

2025 ESC Guidelines on INR Targets in Mechanical Valves INR Targets in Patients With Mechanical Heart Valves Updated, guideline-oriented review Mechanical heart valves are inherently thrombogenic and require lifelong anticoagulation. Vitamin K antagonists, particularly warfarin, remain the standard therapy. The international normalized ratio (INR) is used to guide anticoagulation intensity and must be individualized based on valve type, valve position, and patient-related thromboembolic risk factors. Subtherapeutic INR increases the risk of valve thrombosis and systemic embolism, whereas excessive anticoagulation increases bleeding risk. Why INR control is critical Mechanical valves promote thrombosis due to non-physiological blood flow, high shear stress, and continuous contact between blood and artificial surfaces. These prothrombotic mechanisms persist for life. Direct oral anticoagulants are contraindicated in mechanical valves; therefore, VKAs remain mandatory. The goal of I...

Dr. Usman's Cardiology Notes

Search This Blog